

# Hodgkin Lymphoma Pathways

Patient Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Member Number: \_\_\_\_\_ Treatment Start Date: \_\_\_\_\_

**Pathology:** \_\_\_\_\_ **Stage:** \_\_\_\_\_

**Line of Therapy:** \_\_1<sup>st</sup> Line \_\_2<sup>nd</sup> Line \_\_3<sup>rd</sup> Line \_\_3<sup>rd</sup> Line+ **ECOG Performance Status:** \_\_\_\_\_ **ICD-10 Code:** \_\_\_\_\_

**Biomarkers/Characteristics:** (select all that apply)

CD20 status: \_\_Negative \_\_Positive HIV associated lymphoma: \_\_No \_\_Yes Transplant Candidate: \_\_No \_\_Yes

## Classical Hodgkin Lymphoma | Early Stage (Stage I-IIA, Favorable and Unfavorable Risk)

\_\_\_**ABVD:** doxorubicin (Adriamycin), bleomycin, vinblastine, and dacarbazine (DTIC) ± ISRT\*

## Classical Hodgkin Lymphoma | Advanced Stage (Stage IIB, III, and IV)

\_\_\_**ABVD:** doxorubicin (Adriamycin), bleomycin, vinblastine, and dacarbazine (DTIC) ± ISRT\*

\*ISRT – Involved site radiation therapy

**Note:** Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.

